Member Info for Lastofthesummer

Daniel

I would agree with you over a few weeks delay but this dates back to November 1st RNS ! see below

1 Nov 2023 07:00

RNS Number : 9408R

Caracal Gold PLC

01 November 2023

Caracal Gold plc

('Caracal' or the 'Company')

Delay to Publication of Annual Report and Accounts

Further to the announcement on 24 October 2023 regarding the Delay to Publication of Annual Report and Accounts, Caracal is clarifying the reason for delay in publication.

The Company has made good progress on the audit for the year ended 30 June 2023. However, due to a lack of internal resource, difficulty in arranging field work with the Company's auditors, the reduced number of auditors willing to undertake work for Public Interest Entities ("PIE") (such as the Company) and the Company's own cash constraints, the Company is unable to complete its audit within the required timeframe. The Company has since raised further funds and taken on further consultants to assist the Company to meet its reporting obligations going forward.

What on earthworks are they doing with the audit and getting the shares relisted?. There will for sure be an exodus of shareholders when they do finally get trading again and they can "reset" their story. What I am completly flummaxed about is why its taking soooo long. They are more inept than I think or some really bad news is lurking out there .

Frustrated is now an understatement ! Rant over

Most of here , I think , are here for the Cancer Platforms. I have never really understood the Build and grow strategy for the Diagnostic business. Probably a " My bad" moment and me not understanding the synergy value in the science across the 2 arms of the business.

That said given that we have the Diagnostics Business which I assume could be easily divested or just seperately listed. Does anyone have a feeling for the value of the Diagnostics part of the busines after the most recent bolt on purchases.

Given the Mkt Cap now languishes at 168m what proportion that is covere by the Diagnostics division ?

Any Thoughts ?

A pleasant surprise RNS . If it reduces the need for the customary multiple raises at discounted prices then that a most welcome change from the AIM modus operandi. I can't help thinking the large chunk owned by Alba will drive more sensible financing decision as they won't want to dilute that holding. Encouraging

The point stands though :)

A pleasant surprise RNS . If it reduces the need for the customary multiple raises at discounted prices then that a most welcome change from the AIM modus operandi. I can't help thinking the large chunk owned by Alba will drive more sensible financing decision as they won't want to dilute that holding. Encouraging

Ground Hog Share. I awake every day . I hit the RNS feed looking for the " Caracel share being relisted RNS" . It is'nt there . I curse Robbie .

I for the life of me can't even conceptualise how an audit of a small gold producer takes this much time .

No further RNS needs to issued as far as I can see. Yesterdays RNS included the links to the Poster and put it onto the Companies' Website so that effectively briefed the Investment community.

All

Below is a copy paste from the results/conclusion section of the poster. My Laymans reading of it is the science works in that concentration of dioxrubin in the tumour is seen. But ...

I am unclear if their these are good results in terms of stopping the cancer . Anyone know ?

I note that there appear to be side effects. I was rather hoping we were entering a world of " side effect free Chemo " > Having said that is the incidence of side effects materially reduced ? I mean if a side effect was 100% and is now less than 50% that's presumably a good thing.

Being dumb I know just looking for a bit of insight from those who are more used to reading these poster exerts

here is the copy/paste

Results: Forty patients (median age 65 years, range 30-79), with median 3 prior lines of therapy (range, 0-7) received escalating AVA6000 doses from 80mg/m2 (51 mg/m2 doxorubicin; molar equivalent, 0.675) to 385 mg/m2 (260 mg/m2 doxorubicin equivalent). Tumor types included soft tissue sarcoma (30%), colorectal cancer (27.5%), pancreatic cancer (20%), cancers of the biliary tract (7.5%). The safety profile was favorable, the most frequent adverse events (any grade) being fatigue (50%), alopecia (42.5%), and nausea (32.5%), with rare grade 3-4 hematologic toxicities of neutropenia (7.5%), anemia, thrombocytopenia, and WBC decreased (5% each). Grade 3 non-hematologic toxicities included mucositis, fatigue and hematemesis (n=1 each). No grade 4 non-hematologic toxicities were reported. Two DLTs were observed of grade 2 cardiac failure (120 mg/m2; LVEF decrease 61 to 39%) and grade 4 neutropenia/ thrombocytopenia (200 mg/m2). AVA6000 distributes rapidly with a t1/2 of 45 min. The Cmax of released doxorubicin was reduced as compared to standard dose doxorubicin (range 78-93% reduction) across dose cohorts. Tumor biopsy data demonstrate concentration of doxorubicin in the TME of mean 860 ng/gm (range 76-2310 ng/gm, n=9). In contrast, blood samples taken with the biopsy demonstrate a circulating free doxorubicin of 8.3 ng/ml (range 2.4-15.9), indicating concentration of doxorubicin in the tumor relative to plasma. Using RECISTv.1.1, one PR (-65%) with duration of 6 months was observed in a patient with undifferentiated pleomorphic sarcoma at 160 mg/m2, and a mixed response in a patient with angiosarcoma (SLD -22%) at 200 mg/m2. The disease control rate was 50%, at 12 wks. In each case, SD > 4 months or PR was associated with high FAP enzyme activity in the on-study tumor biopsy compared to observed disease progression as best response (n=6).

Conclusions: AVA6000 delivers high concentration of doxorubicin to the TME relative to plasma which results in antitumor activity in tumors with high FAP activity. A q2w dose escalation arm is ongoing.

You are a better man than I Dalesman if you can maintain patience. The time taken to get the audit done and the share relisted is just a testament to how inept the Management are. What's especially galling is that this isn't the normal speculative gold discovery play . They have the gold and should be throwing cash off the mining operations!........Places hand on forehead :) GLALTH

They raised in late November to get the funds to complete the DFS and the enviromental impact study. They were oversubscribed and pulled in an additional amout. The cash burn is low so I myself would expect any future funding to be post the DFS ( and a reset share price ) . Hopefully with some offtake deal news and then good things will happen . Again thats logic this is aim ;)

86% increase in the size of the licence logically should help the share price . We know there is good quality graphite insitu in the licence. Looks like the Government being supportive as its green explotation .

I think I am right in sayiing Bernard has 1.5% of the company so approx 1.3M at cuurent value. I think that a sale to Hainan will happen. It is in the CEO's interest if that happens to get as higher price as possible and he has stated that he thinks the company is currently undervalued . So IF a sale does happen it will multibag bag from the current level and surely prompt a special divi . If it does not get taken out its a cash generating asset and that too will infuse the share as producers are valued so much more than that explorers :)

Unlike most AIM Ceo's this Bernard Ayling comes across well in the live presentation . Answers the questions without avoidance . Knows the detail and has the credo of actually delivering.

Confident on production going live this year . Fully aware an unstressed about the licence transfer . Indicating an increase in MRE and production in due course . Fully funded. Getting on with JV partner . What's not to like ?

GLA LTH

Muppet Try this . Live now . It might work

https://presentations.investormeetcompany.com/conferences/e31b2f377ace/bigroom

This is getting farcical .... surely no one can dispute they have had more than enough time to get the audit done and the share suspension lifted .... Operationally something must be happening ??? They were supposedly producing gold. At least let us know what the paln is for the raise in terms of attempting to get a positive cash flow .

My only hope is that the fact finance is being injected means someone with more knowledge than us on the BB knows there is a route to get the gold out of the ground

Shocking management to date of a possibly decent resource . V Frustrated . Rant Over :)

Lets not be pessismistic...theres no need today ..:)

....i feel the pain of other ling term investors..dewatering ..bats ..miscellaneous faux pas ...so lets try and enjoy the moment..yes its a small first sample but they are exceptional levels of gold ..at a mining level that is open ..we are invested for gold recovery and now we know its insitu and possibly at quantity..enjoy the moment GLALTH

Sensible RNS today . These small AIm plays need focus and to execute on one value creating strategy . They are not suited to juggling multiple balls . That just gives the management too much wriggle room and leads to dilution as it consumes cash and takes time.

I am here for the Gas pay off. I aminclined to think that the managements confidence in acheiving that has increased hence they can entertain the Strateic Review the out come of which we can all infer.

I am happy with what has been released today

GLALTH

The BOD have "control" asto when the accounts get published is as much as a Board meeting will be required to sign off the represented accounts from the auditors. They should act in a timely manner but can "can kick" the final sign off in a myriad of ways. No doubt if the company comes back to the market ideally they will want to get the suspension lifted alongside some good news on either production or financing . That will save the share price as much as it can be as the expectation must be it falls when trading starts . There will be sell orders aplenty on Day 1 of resumed trading otherwise

This share is a complete shambles ... went into suspension on 1st November . Now 4 full months on and still not sorted. It is not a complex company by comparative standards . The BOD look inept. The passage of time makes me more and more suspicious. I think Bebeto could be right. There must surely be an increasing chance that this doesn't get back to the market.